Renal and intestinal transport defects in Slc26a6-null mice

Zhaohui Wang, Manoocher Soleimani(New Mexico VA Health Care System), Ursula Seidler(Medizinische Hochschule Hannover), Brigitte Riederer(Medizinische Hochschule Hannover), Biguang Tuo(Zunyi Medical University), Snežana Petrović, Peter S. Aronson(Yale University), Sharon Barone(University of Cincinnati), Tong Wang(Yale University), John N. Lorenz(University of Cincinnati Medical Center)
American Journal of Physiology-Cell Physiology
December 2, 2004
10.1152/ajpcell.00505.2004
Cited by 183

Related Papers

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Metabolic modeling of single Th17 cells reveals regulators of autoimmunity
|Cell|2021|511
Probiotic Escherichia coli Nissle 1917 Inhibits Leaky Gut by Enhancing Mucosal Integrity
|PLoS ONE|2007|478
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
|The Lancet|2021|452
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
|The Lancet|2017|449